RESUMO
Multiple sclerosis (MS) is a neuroinflammatory disease characterized by demyelination and axonal damage of the central nervous system. The pathogenesis of MS has also been linked to vascular inflammation and local activation of the coagulation system, resulting in perivascular fibrin deposition. Treatment of experimental autoimmune encephalomyelitis (EAE), a model of human MS, with antithrombotic and antiinflammatory activated protein C (APC) reduces disease severity. Since recombinant APC (Drotecogin alfa), originally approved for the treatment of severe sepsis, is not available for human MS studies, we tested the hypothesis that pharmacologic activation of endogenous protein C could likewise improve the outcome of EAE. Mice were immunized with murine myelin oligodendrocyte glycoprotein (MOG) peptides and at the onset of EAE symptoms, were treated every other day with either WE thrombin (25 µg/kg; i.v.), a selective recombinant protein C activator thrombin analog, or saline control. Mice were monitored for changes in disease score until euthanized for ex vivo analysis of inflammation. Administration of WE thrombin significantly ameliorated clinical severity of EAE, reduced inflammatory cell infiltration and demyelination, suppressed the activation of macrophages comprising the CD11b + population and reduced accumulation of fibrin (ogen) in the spinal cord. These data suggest that symptomatic MS may respond to a treatment strategy that involves temporal pharmacological enhancement of endogenous APC generation.
Assuntos
Encefalomielite Autoimune Experimental/tratamento farmacológico , Proteína C/agonistas , Trombina/uso terapêutico , Animais , Avaliação Pré-Clínica de Medicamentos , Encefalomielite Autoimune Experimental/etiologia , Encefalomielite Autoimune Experimental/patologia , Ativação Enzimática , Fibrina/análise , Fibrinogênio/análise , Humanos , Molécula 1 de Adesão Intercelular/biossíntese , Ativação de Macrófagos , Masculino , Camundongos , Esclerose Múltipla , Glicoproteína Mielina-Oligodendrócito/imunologia , Fragmentos de Peptídeos/imunologia , Mutação Puntual , Proteína C/metabolismo , Medula Espinal/patologia , Baço/imunologia , Baço/patologia , Trombina/genética , Resultado do Tratamento , Fator de Necrose Tumoral alfa/biossíntese , Substância Branca/patologiaRESUMO
BACKGROUND: In fracture treatment, adequate fixation of implants is crucial to long-term clinical performance. Bisphosphonates (BP), potent inhibitors of osteoclastic bone resorption, are known to increase peri-implant bone mass and accelerate primary fixation. However, adverse effects are associated with systemic use of BPs. Thus, Zoledronic acid (ZOL) a potent BP was loaded on bone screws and evaluated in a local delivery model. Whilst mid- to long-term effects are already reported, early cellular events occurring at the implant/bone interface are not well described. The present study investigated early tissue responses to ZOL locally delivered, by bone screw, into a compromised cancellous bone site. METHODS: ZOL was immobilized on fibrinogen coated titanium screws. Using a bilateral approach, ZOL loaded test and non-loaded control screws were implanted into femoral condyle bone defects, created by an overdrilling technique. Histological analyses of the local tissue effects such as new bone formation and osteointegration were performed at days 1, 5 and 10. RESULTS: Histological evaluation of the five day ZOL group, demonstrated a higher osseous differentiation trend. At ten days an early influx of mesenchymal and osteoprogenitor cells was seen and a higher level of cellular proliferation and differentiation (p < 5%). In the ZOL group bone-to-screw contact and bone volume values within the defect tended to increase. Local drug release did not induce any adverse cellular effects. CONCLUSION: This study indicates that local ZOL delivery into a compromised cancellous bone site actively supports peri-implant osteogenesis, positively affecting mesenchymal cells, at earlier time points than previously reported in the literature.
Assuntos
Reabsorção Óssea/prevenção & controle , Parafusos Ósseos , Materiais Revestidos Biocompatíveis , Difosfonatos/farmacologia , Fêmur/efeitos dos fármacos , Imidazóis/farmacologia , Animais , Difosfonatos/administração & dosagem , Difosfonatos/farmacocinética , Avaliação Pré-Clínica de Medicamentos , Exsudatos e Transudatos , Fêmur/patologia , Fibrina/análise , Fibrinogênio , Fibrose , Imidazóis/administração & dosagem , Imidazóis/farmacocinética , Implantes Experimentais , Macrófagos/patologia , Masculino , Mesoderma/patologia , Osseointegração , Osteoclastos/efeitos dos fármacos , Projetos Piloto , Coelhos , Titânio , Ácido ZoledrônicoRESUMO
BACKGROUND: Platelet-rich plasma consists of platelets concentrated in a small volume of plasma and constitutes a reservoir of bio-modulators potentially useful in tissue repair. The amounts of bio-modulators detectable in platelet-rich plasma prepared with various commercial or "in house" methods have been reported, but virtually all the analyses described have been performed on platelet-rich plasma derived from healthy donors. Since leucocyte contamination is technically unavoidable, we investigated whether platelet-rich plasma prepared from patients could contain different amounts of bio-modulators because of a possible activated status of the leucocytes. MATERIALS AND METHODS: We evaluated platelet-rich plasma prepared with three different techniques (the commercial Vivostat and Biomet recover GPS II systems and an "in house" method) starting from whole blood from healthy donors and patients. Specifically, we compared the levels of sHLA-I, sFasL, platelet-derived growth factor, transforming growth factors-beta and vascular endothelial growth factor in the platelet-rich plasma releasates according to the method of preparation and to the immune system activation status of the subjects. RESULTS: With the exception of sHLA-I levels, no differences were found in the surrogate indices of lymphocyte activation between healthy donors and patients. No significant differences were found in sHLA-I, sFasL, platelet-derived growth factor, transforming growth factors-beta and vascular endothelial growth factor levels detectable in platelet-rich plasma produced with the three different methods in either healthy donors or patients. DISCUSSION: On the whole our findings indicate that the overall content of bio-modulators in autologous platelet-rich plasma is not influenced by T-lymphocyte activation status, at least in patients with uncomplicated femoral fractures. The amounts of sFasL and sHLA-I detected in all the platelet-rich plasma releasates studied were very small, far below the amounts detectable in all clinically available blood derivatives and absolutely insufficient to induce sHLA-I and/or sFasL mediated immunomodulation.
Assuntos
Remoção de Componentes Sanguíneos/métodos , Doadores de Sangue , Proteína Ligante Fas/sangue , Antígenos HLA/sangue , Peptídeos e Proteínas de Sinalização Intercelular/sangue , Leucócitos/química , Plasma Rico em Plaquetas , Adulto , Anticoagulantes/farmacologia , Batroxobina/farmacologia , Preservação de Sangue , Transfusão de Sangue Autóloga , Ácido Cítrico/farmacologia , Fibrina/análise , Géis , Glucose/análogos & derivados , Glucose/farmacologia , Humanos , Contagem de Leucócitos , Ativação Linfocitária , Masculino , Contagem de Plaquetas , SolubilidadeRESUMO
OBJECTIVE: The present study histologically and radiologically evaluates the muscle tissue of rats after implantation of bone morphogenic protein (rhBMP-2) in a natural inorganic bone mineral scaffold from a bull calf femur and irradiation with low-power light laser. MATERIALS AND METHODS: The right and left hind limbs of 16 rats were shaved and an incision was made in the muscle on the face corresponding to the median portion of the tibia, into which rhBMP-2 in a scaffold of inorganic bone was implanted. Two groups of limbs were formed: control (G1) and laser irradiation (G2). G2 received diode laser light applied in the direction of the implant, at a dose of 8 J/cm2 for three minutes. On the 7th, 21st, 40th and 112th days after implantation, hind limbs of 4 animals were radiographed and their implants removed together with the surrounding tissue for study under the microscope. The histological results were graded as 0=absence, 1=slight presence, 2=representative and 3=very representative, with regard to the following events: formation of osteoid structure, acute inflammation, chronic inflammation, fibrin deposition, neovascularization, foreign-body granuloma and fibrosis. RESULTS: There were no statistically significant differences in these events at each evaluation times, between the two groups (P > 0.05; Mann-Whitney test). Nevertheless, it could be concluded that the natural inorganic bone matrix with rhBMP-2, from the femur of a bull calf, is a biocompatible combination. CONCLUSIONS: Under these conditions, the inductive capacity of rhBMP-2 for cell differentiation was inhibited. There was a slight acceleration in tissue healing in the group that received irradiation with low-power laser light.
Assuntos
Matriz Óssea/transplante , Proteínas Morfogenéticas Ósseas/uso terapêutico , Músculo Esquelético/patologia , Proteínas Recombinantes/uso terapêutico , Alicerces Teciduais , Fator de Crescimento Transformador beta/uso terapêutico , Implantes Absorvíveis , Animais , Materiais Biocompatíveis/uso terapêutico , Matriz Óssea/efeitos dos fármacos , Matriz Óssea/efeitos da radiação , Proteína Morfogenética Óssea 2 , Proteínas Morfogenéticas Ósseas/administração & dosagem , Proteínas Morfogenéticas Ósseas/efeitos da radiação , Bovinos , Diferenciação Celular/efeitos dos fármacos , Diferenciação Celular/efeitos da radiação , Fibrina/análise , Fibrose , Granuloma de Corpo Estranho/etiologia , Granuloma de Corpo Estranho/patologia , Inflamação , Lasers Semicondutores/uso terapêutico , Terapia com Luz de Baixa Intensidade/métodos , Masculino , Músculo Esquelético/diagnóstico por imagem , Músculo Esquelético/cirurgia , Neovascularização Fisiológica/efeitos dos fármacos , Neovascularização Fisiológica/efeitos da radiação , Osteogênese/efeitos dos fármacos , Osteogênese/efeitos da radiação , Doses de Radiação , Radiografia , Ratos , Ratos Wistar , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/efeitos da radiação , Fatores de Tempo , Fator de Crescimento Transformador beta/administração & dosagem , Fator de Crescimento Transformador beta/efeitos da radiação , Cicatrização/efeitos dos fármacos , Cicatrização/efeitos da radiaçãoRESUMO
Attenuation of inflammatory cell deposits and associated cytokines prevented the apoptosis of transplanted stem cells in a sciatic nerve crush injury model. Suppression of inflammatory cytokines by fermented soybean extracts (Natto) was also beneficial to nerve regeneration. In this study, the effect of Natto on transplanted human amniotic fluid mesenchymal stem cells (AFS) was evaluated. Peripheral nerve injury was induced in SD rats by crushing a sciatic nerve using a vessel clamp. Animals were categorized into four groups: Group I: no treatment; Group II: fed with Natto (16 mg/day for 7 consecutive days); Group III: AFS embedded in fibrin glue; Group IV: Combination of group II and III therapy. Transplanted AFS and Schwann cell apoptosis, inflammatory cell deposits and associated cytokines, motor function, and nerve regeneration were evaluated 7 or 28 days after injury. The deterioration of neurological function was attenuated by AFS, Natto, or the combined therapy. The combined therapy caused the most significantly beneficial effects. Administration of Natto suppressed the inflammatory responses and correlated with decreased AFS and Schwann cell apoptosis. The decreased AFS apoptosis was in line with neurological improvement such as expression of early regeneration marker of neurofilament and late markers of S-100 and decreased vacuole formation. Administration of either AFS, or Natto, or combined therapy augmented the nerve regeneration. In conclusion, administration of Natto may rescue the AFS and Schwann cells from apoptosis by suppressing the macrophage deposits, associated inflammatory cytokines, and fibrin deposits.
Assuntos
Transplante de Células-Tronco Mesenquimais , Compressão Nervosa/reabilitação , Regeneração Nervosa/efeitos dos fármacos , Fitoterapia , Extratos Vegetais/uso terapêutico , Nervo Isquiático/efeitos dos fármacos , Alimentos de Soja , Líquido Amniótico/citologia , Animais , Apoptose/efeitos dos fármacos , Citocinas/antagonistas & inibidores , Citocinas/fisiologia , Fibrina/análise , Adesivo Tecidual de Fibrina/toxicidade , Inflamação/patologia , Macrófagos/efeitos dos fármacos , Proteínas do Tecido Nervoso/análise , Extratos Vegetais/administração & dosagem , Ratos , Ratos Sprague-Dawley , Recuperação de Função Fisiológica , Células de Schwann/efeitos dos fármacos , Células de Schwann/patologia , Nervo Isquiático/fisiologiaRESUMO
Although gadolinium has been the dominant paramagnetic metal for MR paramagnetic contrast agents, the recent association of this lanthanide with nephrogenic systemic fibrosis, an untreatable disease, has spawned renewed interest in alternative metals for MR molecular imaging. We have developed a self-assembled, manganese(III)-labeled nanobialys (1), a toroidal-shaped MR theranostic nanoparticle. In this report, Mn(III) nanobialys are characterized as MR molecular imaging agents for targeted detection of fibrin, a major biochemical feature of thrombus. A complementary ability of nanobialys to incorporate chemotherapeutic compounds with greater than 98% efficiency and to retain more than 80% of these drugs after infinite sink dissolution, point to the theranostic potential of this platform technology.
Assuntos
Sistemas de Liberação de Medicamentos/métodos , Angiografia por Ressonância Magnética/métodos , Manganês/química , Nanopartículas/química , Biotina/química , Camptotecina/administração & dosagem , Camptotecina/química , Doxorrubicina/administração & dosagem , Doxorrubicina/química , Fibrina/análise , Fibrina/química , Humanos , Micelas , Microscopia de Força Atômica , Compostos Organometálicos/químicaRESUMO
A 30-year-old woman was admitted to our hospital to undergo simultaneous cesarean section and radical hysterectomy when the pregnancy became 30 weeks. An ultrasonic examination had found hypoechoic region at the cervix uteri. Because she wished autologous blood transfusion, 100 ml each of her own blood was obtained 3 times preoperatively. All the stored blood was returned to the patient through a filtering system (40 microm in the pore size) during surgery. However, we found paste-like agglutinates floating in the bags. We transfused the blood carefully while confirming that there were no agglutinates in the reservoir below the filter. The paste-like agglutinates were also found on the filter. By microscopic observation fibrin-like substances attached by blood cells were detected. When the autologous blood from pregnant women is returned, special care should be taken because the blood is likely to form agglutinates even though the blood test data are within normal ranges.
Assuntos
Preservação de Sangue , Transfusão de Sangue Autóloga , Fibrina/isolamento & purificação , Filtração , Assistência Perioperatória , Adulto , Anestesia Epidural , Anestesia Geral , Anestesia Obstétrica , Raquianestesia , Cesárea , Feminino , Fibrina/análise , Fibrina/ultraestrutura , Humanos , Histerectomia , Microscopia , Gravidez , Complicações Neoplásicas na Gravidez/cirurgia , Neoplasias Uterinas/cirurgiaRESUMO
INTRODUCTION: Disseminated intravascular coagulation in humans is frequently associated with Gram-negative bacterial sepsis. Therefore, to examine the role and time frame of the in vivo induction of tissue factor (TF) by bacterial endotoxin, a reverse transcription polymerase chain reaction and a solid-phase ELISA assay were developed to monitor the in vivo production in rabbits, of TF mRNA and TF antigen by peripheral blood leukocytes (PBL). METHODS: : Healthy rabbits were injected intravenously with either 1, 10 or 50 microg/kg of Salmonella endotoxin. Blood samples were obtained both before endotoxin administration and at various time points thereafter, up to 24 h. Some experiments were also done to determine whether all-trans retinoic acid would ameliorate the signs of the endotoxin-induced disseminated intravascular coagulation. RESULTS: PBL counts dropped significantly within 2 h of rabbits receiving the endotoxin, recovering to baseline levels by 24 h. Platelet counts decreased gradually over this same time frame. Fibrin deposition was noted in renal glomerular capillaries at 24 h. An increase (P<0.001) in PBL-associated TF mRNA levels was observed 2 h post-endotoxin (10 microg/kg, n = 8), followed by a gradual decline over the subsequent 24 h. The average increase in TF mRNA at 2 h was approximately 4.6-fold (P<0.001) over that seen at time 0. The amount of mononuclear cell associated TF antigen demonstrated a peak at 2 h post-endotoxin (10 microg/kg, n = 13), with levels approximately 9.6-fold greater than (P<0.001) baseline. Pre-treatment of rabbits with all-trans retinoic acid significantly (P<0.001) ameliorated the PBL-associated increase in TF mRNA and TF antigen levels. CONCLUSION: These results suggest that low dose endotoxin (10 microg/kg) faithfully reproduces the non-overt activation of coagulation observed in primates and human volunteers, supporting the hypothesis that TF expression is involved in the in vivo initiation and propagation of disseminated intravascular coagulation. Moreover, all-trans retinoic acid may be effective in modulating in vivo the TF transcription induced by endotoxin.
Assuntos
Endotoxemia/sangue , Regulação da Expressão Gênica/efeitos dos fármacos , Leucócitos/metabolismo , RNA Mensageiro/biossíntese , Tromboplastina/biossíntese , Animais , Antitrombina III/análise , Contagem de Células Sanguíneas , Coagulação Intravascular Disseminada/sangue , Coagulação Intravascular Disseminada/etiologia , Coagulação Intravascular Disseminada/patologia , Coagulação Intravascular Disseminada/prevenção & controle , Avaliação Pré-Clínica de Medicamentos , Endotoxemia/complicações , Endotoxemia/tratamento farmacológico , Endotoxemia/genética , Endotoxemia/patologia , Fibrina/análise , Fibrinogênio/análise , Glomérulos Renais/química , Lipopolissacarídeos/toxicidade , Masculino , Coelhos , Trombocitopenia/etiologia , Tromboplastina/genética , Tretinoína/farmacologia , Tretinoína/uso terapêuticoRESUMO
This study investigates the association between the concentration and function of plasma fibrinogen molecules measured at the time of hospital admission in patients with acute myocardial infarction (AMI), with reference to the risk of new coronary ischemic events during a three-day follow-up period of. Before starting fibrinolytic and anticoagulant treatment plasma fibrinogen, high molecular weight fibrinogen (HMW-fibrinogen), fibrin formation rate (FbFR) and phosphorous content in fibrinogen were determined in 90 AMI patients. During a three-day follow-up period 12 patients suffered new ischemic events. The 12 patients with coronary ischemia had higher concentrations of plasma fibrinogen (312+/-23 vs. 270+/-73 mg/dl, p<0.05) and HMW-fibrinogen (246+/-35 vs. 189+/-23 mg/dl, p<0.001) and a higher FbFR (65+/-30 vs. 40+/-25, p<0.001) than patients without these events. No association was found between the phosphorous content in fibrinogen and new coronary ischemic events. We conclude that after myocardial infarction an elevated plasma level of HMW-fibrinogen and a high FbFR value at the time of hospital admission are associated with new coronary ischemic events during a three-day follow-up period.
Assuntos
Trombose Coronária/sangue , Fibrinogênio/análise , Infarto do Miocárdio/sangue , Idoso , Biomarcadores , Convalescença , Trombose Coronária/epidemiologia , Feminino , Fibrina/análise , Fibrinogênio/química , Fibrinopeptídeo A/análise , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Peso Molecular , Infarto do Miocárdio/epidemiologia , Fósforo/análise , Fosforilação , Processamento de Proteína Pós-Traducional , RecidivaRESUMO
Achieving early, complete, and sustained reperfusion after acute myocardial infarction does not occur in approximately 50% of patients, even with the most potent established thrombolytic therapy. Bleeding is observed with increased concentrations of thrombolytics as well as with adjunctive antithrombotic and antiplatelet agents. A novel approach to enhance thrombolytic therapy is to inhibit the activated form of thrombin-activatable fibrinolysis inhibitor (TAFI), which attenuates fibrinolysis in clots formed from human plasma. Identification of TAFI in rabbit plasma facilitated the development of a rabbit arterial thrombolysis model to compare the thrombolytic efficacy of tissue-plasminogen activator (tPA) alone or with an inhibitor, isolated from the potato tuber (PTI), of activated TAFI (TAFIa). Efficacy was assessed by determining the time to patency, the time the vessel remained patent, the maximal blood flow achieved during therapy, the percentage of the original thrombus, which lysed, the percentage change in clot weight, the net clot accreted, and the release of radioactive fibrin degradation products into the circulation. The results indicate that coadministration of PTI and tPA significantly improved tPA-induced thrombolysis without adversely affecting blood pressure, activated partial thromboplastin time, thrombin clotting time, fibrinogen, or alpha-2-antiplasmin concentrations. The data indicate that inhibitors of TAFIa may comprise novel and very effective adjuncts to tPA and improve thrombolytic therapy to achieve both clot lysis and vessel patency.
Assuntos
Carboxipeptidases/antagonistas & inibidores , Fibrinólise/efeitos dos fármacos , Infarto do Miocárdio/tratamento farmacológico , Proteínas de Plantas/uso terapêutico , Inibidores de Proteases/uso terapêutico , Terapia Trombolítica/métodos , Animais , Carboxipeptidase B2 , Carboxipeptidases/sangue , Avaliação Pré-Clínica de Medicamentos , Sinergismo Farmacológico , Quimioterapia Combinada , Fibrina/análise , Humanos , Masculino , Infarto do Miocárdio/enzimologia , Tempo de Tromboplastina Parcial , Proteínas de Plantas/farmacocinética , Proteínas de Plantas/farmacologia , Inibidores de Proteases/farmacocinética , Inibidores de Proteases/farmacologia , Coelhos , Organismos Livres de Patógenos Específicos , Ativador de Plasminogênio Tecidual/uso terapêuticoRESUMO
Of 35 acetylsalicylic acid (ASA)-treated patients undergoing coronary artery bypass surgery, 10 received a high dose of aprotinin (mean 5.2 x 10(6) KIU) during cardiopulmonary bypass (CPB); in 15 cases low-dose aprotinin (2 x 10(6) KIU) was added to the CPB priming solution, and 10 patients made up a control group without aprotinin. Median total blood loss was 52% less in aprotinin-treated patients, irrespective of dose, than in the controls. Fibrin-D dimer levels remained low in patients treated with high-dose aprotinin, but increased significantly in the control group. Platelet adhesion and platelet adenosine triphosphate secretion were reduced after CPB in all patients. Whole-blood aggregation after bypass was enhanced in aprotinin-treated patients. Aprotinin inhibited fibrinolysis and seemingly preserved platelet function despite ASA treatment. In view of the possible risks and relatively high cost of aprotinin, use of a high dose seems unnecessary, since a low dose was equally effective in reducing blood loss in ASA-treated patients.
Assuntos
Aprotinina/administração & dosagem , Perda Sanguínea Cirúrgica/prevenção & controle , Ponte Cardiopulmonar , Hemostáticos/administração & dosagem , Trifosfato de Adenosina/metabolismo , Adulto , Idoso , Angina Instável/tratamento farmacológico , Angina Instável/cirurgia , Aspirina/efeitos adversos , Aspirina/uso terapêutico , Transfusão de Sangue , Intervalos de Confiança , Relação Dose-Resposta a Droga , Feminino , Fibrina/análise , Fibrinolíticos/efeitos adversos , Fibrinolíticos/uso terapêutico , Humanos , Injeções Intravenosas , Masculino , Pessoa de Meia-Idade , Adesividade Plaquetária/efeitos dos fármacos , Contagem de Plaquetas/efeitos dos fármacos , Cuidados Pré-Operatórios , Valores de Referência , Resultado do TratamentoRESUMO
The degenerating tissues found in rat periodontal ligaments during tooth movement were examined morphologically, histochemically, and elementally, with decalcified and unfixed, undecalcified frozen sections. There were two types of degenerating tissues found in the compressed periodontal ligaments: One (type A tissue) was stained differently from collagen and the other (type B tissue) showed the same color as collagen. Type A tissue also showed the deposition of fibrin in Martius scalet blue and Weigert stain. The electron micrograph also showed the deposition of fibrin in type A tissue. No collagen fibers with typical bandings were seen in either tissue. The digestion experiment showed that type A tissue was digested by trypsin but not type B, whereas most of type B tissue was digested by collagenase but not type A. The backscattered electron image by scanning electron microscopy of type A tissue of the unfixed undecalcified frozen sections showed the presence of many small pieces. The elemental analysis of the pieces showed high peaks of phosphorous and calcium. These results indicate that collagen degradation, fibrin deposition, and calcification occurred in the degenerating tissues, especially in type A tissue during the experimental tooth movement.
Assuntos
Compostos Azo , Ligamento Periodontal/patologia , Técnicas de Movimentação Dentária , Animais , Calcinose/patologia , Cálcio/análise , Colágeno/análise , Colagenases , Corantes , Técnica de Descalcificação , Microanálise por Sonda Eletrônica , Fibrina/análise , Fixadores , Secções Congeladas , Histocitoquímica , Masculino , Microscopia Eletrônica , Microscopia Eletrônica de Varredura , Inclusão em Parafina , Ligamento Periodontal/química , Ligamento Periodontal/diagnóstico por imagem , Fósforo/análise , Ratos , Ratos Wistar , Tripsina , UltrassonografiaRESUMO
We investigated the protective effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against two kinds of experimental disseminated intravascular coagulation (DIC) in rats. Endotoxin-induced experimental DIC was induced by a 4-h sustained infusion of endotoxin at a dose of 100 mg/kg. Thromboplastin-induced experimental DIC was induced by a bolus injection of thromboplastin at a dose of 150 mg/kg. The rats were orally administered DX-9065a at 10, 30 or 100 mg/kg 30 min before endotoxin or thromboplastin injection. In both DIC models, DX-9065a showed a protective effect against DIC, at all doses and in all parameters, including fibrin/fibrinogen degradation products (FDP), fibrinogen level, prothrombin time, activated partial thromboplastin time, platelet count and the number of renal glomeruli with fibrin thrombi. When DX-9065a was orally administrated at 100 mg/kg without endotoxin or thromboplastin, no significant changes were seen in hemostatic parameters except PT and APTT, and no fibrin thrombi or abnormal bleeding were seen in renal specimens. These findings suggest that the new oral anti-Xa drug, DX-9065a, has an effect in reducing the severity of DIC. However, further dose-finding and safety studies of this drug have still to be assessed.
Assuntos
Anticoagulantes/uso terapêutico , Coagulação Intravascular Disseminada/tratamento farmacológico , Inibidores do Fator Xa , Naftalenos/uso terapêutico , Propionatos/uso terapêutico , Administração Oral , Animais , Anticoagulantes/administração & dosagem , Coagulação Intravascular Disseminada/sangue , Coagulação Intravascular Disseminada/induzido quimicamente , Coagulação Intravascular Disseminada/patologia , Avaliação Pré-Clínica de Medicamentos , Endotoxinas/toxicidade , Fibrina/análise , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Fibrinogênio/análise , Glomérulos Renais/patologia , Masculino , Naftalenos/administração & dosagem , Tempo de Tromboplastina Parcial , Contagem de Plaquetas , Propionatos/administração & dosagem , Tempo de Protrombina , Ratos , Ratos Wistar , Tromboplastina/toxicidadeRESUMO
Immunohistochemical study of tissues from purulent wounds in rats after treatment with the collagenase isolated from the King crab Paralithodes camtschatica was undertaken. The enzymotherapy resulted in a rapid and efficient removal of necrotic debris. It was accompanied by fibrin elimination from the wound bed and subsequent formation of new capillaries. Cellular fibronectin with ED-A sequence was identified in the newly formed granulation tissue, which points to its active synthesis in situ. Polyclonal antibodies against two isozymes of the crab collagenolytic protease were obtained. By their use it was shown that, after application of the collagenase, both isozymes accumulated in fibrin deposits at the wound bed but did not penetrate adherent granulation tissue.
Assuntos
Braquiúros/enzimologia , Colagenases/uso terapêutico , Infecção dos Ferimentos/tratamento farmacológico , Animais , Anticorpos/análise , Anticorpos/imunologia , Colagenases/imunologia , Colagenases/farmacologia , Fibrina/análise , Fibronectinas/análise , Tecido de Granulação/química , Tecido de Granulação/efeitos dos fármacos , Tecido de Granulação/patologia , Imuno-Histoquímica , Isoenzimas/imunologia , Ratos , Ratos Wistar , Cicatrização/efeitos dos fármacos , Infecção dos Ferimentos/patologiaRESUMO
A rat thrombosis model was developed to assess the efficacity of antithrombotic drugs. It had the following characteristics: controlled hemodynamic and rheological conditions corresponding to arterial flow, a collagen coated surface as a relevant thrombogenic stimulus, a method of measurement allowing dynamic monitoring of thrombus formation and the possibility to assess the thrombus structure. A shunt composed of polyethylene and silicone catheters, including in the middle of the shunt a collagen coated glass capillary, was inserted between the two primitive carotids of the rat. The duration of patency of the shunt was recorded using a thermic probe fixed on its central part. In this model, the patency of the shunt was 539 +/- 55 s. Platelet and fibrinogen-fibrin accumulation in successive one centimeter segments along the shunt were measured using 111In labeled platelets and 125I labeled fibrinogen. Platelet accumulation occurred on the collagen coated surface and at the junctions between the different components of the shunt, where flow was disturbed. The effects of four antithrombotic agents were measured: aspirin, clopidogrel, heparin and r-hirudin. Clopidogrel, heparin and hirudin significantly prolonged patency duration of the shunt, whereas aspirin was inactive. Aspirin did not reduce platelet or fibrinogen-fibrin accumulation on the collagen coated surface. Platelet accumulation on the collagen surface was significantly lower in the clopidogrel group (50 mg/kg) than in the group treated with heparin (500 U/kg), demonstrating the direct antiplatelet effect of clopidogrel. Hirudin at doses giving similar values of APTT as heparin (500 U/kg) prolonged the occlusion time to over 2 h while the heparin occlusion time was only 20 min.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Anticoagulantes/uso terapêutico , Fístula Artério-Arterial , Trombose das Artérias Carótidas/prevenção & controle , Colágeno , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos/métodos , Fibrinolíticos/uso terapêutico , Adesividade Plaquetária/efeitos dos fármacos , Inibidores da Agregação Plaquetária/uso terapêutico , Trombina/biossíntese , Animais , Anticoagulantes/farmacologia , Aspirina/farmacologia , Aspirina/uso terapêutico , Trombose das Artérias Carótidas/tratamento farmacológico , Clopidogrel , Fibrina/análise , Fibrinogênio/análise , Fibrinolíticos/farmacologia , Vidro , Heparina/farmacologia , Heparina/uso terapêutico , Terapia com Hirudina , Hirudinas/farmacologia , Masculino , Inibidores da Agregação Plaquetária/farmacologia , Polietilenos , Ratos , Ratos Wistar , Proteínas Recombinantes/farmacologia , Proteínas Recombinantes/uso terapêutico , Fluxo Sanguíneo Regional , Silicones , Ticlopidina/análogos & derivados , Ticlopidina/farmacologia , Ticlopidina/uso terapêuticoRESUMO
Recombinant (r) hirudin is a potent thrombin-specific inhibitor originally derived from the natural hirudin of the leech (Hirudo medicinalis). We have studied the efficacy of r-hirudin compared to heparin in a dog model of cardiopulmonary bypass (CPB) surgery. Two administration regimens were used for r-hirudin: Group I received 1.0 mg/kg intracardiac (i.c.) bolus then intravenous (i.v.) bolus at 30 min (n = 10); Group II received 1.0 mg/kg (i.c.) bolus with 1.25 +/- 0.04 mg/kg/h (i.v.) infusion (n = 8). Group III was given heparin 1.66 mg/kg (i.c.) bolus (n = 9). Aspiration of blood from the chest cavity revealed no significant difference between the three groups. Measurement of fibrin deposits in the pump line filter revealed higher amounts in the r-hirudin groups (P = 0.02). Decreases in platelets, fibrinogen and haematocrit due primarily to haemodilution were the same in each group. The bleeding time was less prolonged for r-hirudin than for heparin (p less than 0.001). No antagonist for r-hirudin was used; however, due to its short half-life, all coagulation parameters returned to baseline within 30 min after CPB. Since r-hirudin has no effect on platelets, is a poor immunogen, does not require a plasma cofactor, and may not require an antagonist, it may provide an alternative anticoagulant to heparin in CPB. Additional studies are, however, needed to optimize the dose and to evaluate other clinical aspects of r-hirudin.
Assuntos
Ponte Cardiopulmonar , Heparina/uso terapêutico , Terapia com Hirudina , Trombose/prevenção & controle , Animais , Tempo de Sangramento , Perda Sanguínea Cirúrgica , Ponte Cardiopulmonar/efeitos adversos , Cães , Circulação Extracorpórea , Fibrina/análise , Hematócrito , Heparina/farmacologia , Hirudinas/administração & dosagem , Hirudinas/farmacologia , Infusões Intravenosas , Injeções , Masculino , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/farmacologia , Proteínas Recombinantes/uso terapêutico , Tempo de Trombina , Trombose/etiologiaRESUMO
The hyperacute form of experimental allergic encephalomyelitis (EAE), characterized by a short incubation period, severe paralysis, high mortality, and abundant polymorphonuclear leukocytes and fibrin in the lesions, was produced in rats without the use of pertussis vaccine (previously considered an essential requirement) or Freund's adjuvant. Carbonyl iron or mineral oil without mycobacteria were effective adjuvants and whole rat spinal cord was the best antigen. Hyperacute EAE was produced in this manner in some Lewis rats, most dark agouti (DA) rats and most F1 hybrids of these two strains. Clinical signs were earlier in onset and more severe in the DA strain than in the Lewis strain in all adjuvant-antigen combinations that were tested. Dark agouti rats developed clinical signs in six days, histological lesions in five days, and localized EAE lesions could be induced in four days. The data support the hypothesis that hyperacute type lesions (neutrophils and fibrin) can be caused by an exceptionally strong immune response to neural antigen, whether that response is engendered by a particular adjuvant (pertussis vaccine) or by an unusual degree of genetic susceptibility (DA rats).
Assuntos
Encefalomielite Autoimune Experimental/imunologia , Vacina contra Coqueluche , Adjuvantes Imunológicos , Animais , Antígenos/imunologia , Encefalomielite Autoimune Experimental/patologia , Feminino , Fibrina/análise , Adjuvante de Freund , Histocitoquímica , Imunização , Compostos Carbonílicos de Ferro , Linfonodos/patologia , Óleo Mineral , Neutrófilos/patologia , Compostos Organometálicos/imunologia , Ratos , Ratos Endogâmicos Lew , Hipoclorito de Sódio/farmacologia , Medula Espinal/imunologia , Medula Espinal/patologiaRESUMO
Hydrolysis of plasminogen permits obtaining its nine fragments. The method of differential scanning microcalorimetry reveals seven domains in plasminogen, and the affinity chromatography--three lysin- and three arginyl-binding sites. The lysin-binding sites of domains (Kringles) K1 and K4 differ in ligand specificity. Benzamidine-binding sites of domain K5 and of plasmin light chain are simultaneously arginine-binding ones. The third arginyl-binding site differing from the benzamidine-binding one is found in fragment K1-3. In the plasminogen-fibrin interaction only lysin-binding sites of plasminogen take part; in the plasminogen fragments-fibrinogen fragments interaction both types of plasminogen sites participate. The heavy chain of plasmin interacts with the E-fragment of fibrinogen by the lysin-binding sites, and the light chain of plasmin interacts with D-fragment of fibrinogen by arginyl-binding sites. Sites complementary to arginyl binding sites of plasminogen are located on the DH-fragment and sites of interaction with lysin- and arginyl-binding sites--on the DL-fragment. The plasmin-fibrin interaction mediated by sites of the first four cringles is not associated with changes in the catalytic function of the active centre. Interaction of Lys-plasminogen with fibrin accelerates polymerization of the latter. The effect of Lys-plasminogen is conditioned by the lysin-binding sites. Glu-plasminogen has no effect on the polymerization process.
Assuntos
Arginina/análise , Lisina/análise , Fragmentos de Peptídeos/análise , Plasminogênio/análise , Sítios de Ligação , Varredura Diferencial de Calorimetria , Cromatografia de Afinidade , Fibrina/análise , Produtos de Degradação da Fibrina e do Fibrinogênio/análise , Fibrinolisina/análise , Técnicas In Vitro , LigantesRESUMO
One hundred provoked normovolemic hemodilutions, which were associated with autotransfusion, have been performed in ninety-three children during a period of sixteen months. This study shows a significant saving of homologous blood (thirteen children, only had to be transfused). The mean difference in the hemoglobin level before and after surgery was of 2.1 g/100 ml. This technic did not result in any complication.